Basilea Pharmaceutica - Strong Cresemba traction triggers milestone payment
Continued strong sales of Cresemba, Basilea Pharmaceutica’s lead antifungal asset, in the Asia-Pacific region and China, has triggered the receipt...
237 Views
Basilea Pharmaceutica - From strength to strength
FY23 was another strong year for Basilea, marked by successive guidance beats and meaningful progress in fortifying its product pipeline. Revenues...
187 Views
Basilea Pharmaceutica - Strong close to FY23 with another milestone payment
Basilea has announced receipt of its first sales-related milestone (for an undisclosed amount) from distribution partner Knight Therapeutics. The...
338 Views
Basilea Pharmaceutica - Antibiotic addition to further replenish pipeline
Basilea has announced a preclinical antibiotic programme asset purchase agreement, aligning with management’s pre-emptive efforts to refill its...
156 Views
Basilea Pharmaceutica - Refilling the pipeline for growth
Basilea recently expanded its antifungal and antibacterial product pipeline with three new assets, including the latest addition, fosmanogepix. As...
624 Views